GLP Weight Loss · Compounded
Weight management with a dual-agonist option, reviewed by a licensed provider.
Compounded tirzepatide — a dual GLP-1 and GIP option — for patients a provider determines are candidates, with follow-up built in.
Two quick questions
$197/mo$591 for 90 daysAs low as $186/mo · $1,116 for 180 daysShipping included. Prepaid multi-month pricing is locked at purchase.
Compounded medications are prepared by licensed U.S. compounding pharmacies for an individual patient under a prescription. They are not approved by the FDA and have not been evaluated by the FDA for safety, effectiveness, or quality.
We're in final testing before launch. You can walk through the full intake to see how it works — it is not submitted, and no treatment, prescription or payment is processed yet.
Intake and health information are handled by the licensed telehealth platform; this website never collects health information.
How it works
Four steps, every program.
The clinical review is never skipped, whatever you come here for.
- Intake.A private form inside a secure, HIPAA-compliant platform.
- Licensed-provider review.A licensed U.S. provider evaluates your intake and decides on treatment, which is never guaranteed.
- Shipment.The medication ordered is shipped discreetly to your home from a licensed 503A compounding pharmacy and typically arrives within 1–3 business days.
- Ongoing care.If prescribed, your care team follows up and adjusts the plan as needed.
Why tirzepatide
One molecule, two pathways — and a provider who decides which program fits.
Tirzepatide is a dual agonist: it acts on both the GLP-1 receptor and the GIP receptor, where semaglutide acts on the GLP-1 receptor alone. That is the whole of the difference this page states — it is a fact about the molecule, not a claim about results.
The compounded tirzepatide in this program is prepared by a licensed 503A compounding pharmacy for you individually and is not FDA-approved. The FDA-approved tirzepatide products carry their own labeling, which is the source for the safety statements on this page.
Which GLP-1 program is right for you is a clinical decision. A licensed provider reviews your history and may recommend semaglutide, tirzepatide, or neither. Choosing the higher-priced program is not a way to buy a stronger result — it is a different medication, prescribed when it is the appropriate one.
Evidence and sources
What the sources say.
Every clinical statement on this page carries its source and the date it was last reviewed.
- Tirzepatide carries a boxed warning for thyroid C-cell tumors and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Compounded GLP-1 medications are not FDA-approved and the FDA does not review them for safety, effectiveness, or quality.
Safety and candor
Not for everyone — and that is the point of the review.
Compounded medications are prepared by licensed U.S. compounding pharmacies for an individual patient under a prescription. They are not approved by the FDA and have not been evaluated by the FDA for safety, effectiveness, or quality. Compounded medications have not been evaluated by the FDA for safety or effectiveness.
Not for people with
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy, planning pregnancy, or breastfeeding
- History of pancreatitis
- History of severe gastrointestinal disease, including gastroparesis
Treatment, prescriptions, and eligibility are determined by a licensed provider following an evaluation, and are never guaranteed.
FAQ
Questions
Is a prescription required?
Yes. A licensed provider reviews your intake first. You are only charged for medication if a prescription is written for you.
Which states is this available in?
See the availability page for the current list. The list is updated as coverage changes.